Heron Therapeutics | HRTX - سود ناخالص در فروش





سود ناخالص در فروش تغییر دادن تاریخ
ALKERMES USD 338.34M 72.51M 2025-12
Alnylam Pharmaceuticals USD 829.31M 219.56M 2025-12
Amarin USD 23.17M 961K 2025-12
ANI Pharmaceuticals USD 124.18M 12.39M 2025-12
Anika Therapeutics USD 19.18M 3.6M 2025-12
Arrowhead Research USD 256.47M 228.7M 2025-09
Eisai JPY 168.85B 17.02B 2025-12
Esperion Therapeutics USD 140.59M 94.57M 2025-12
GlaxoSmithKline GBP 6.18B 106M 2025-12
Heron Therapeutics USD 29.47M 3.17M 2025-12
Insmed USD 217.69M 106.25M 2025-12
Ligand Pharmaceuticals USD 155.28M 82.42M 2025-09
Merck USD 13.42B 431M 2025-09
Nektar Therapeutics USD 21.81M 8.06M 2025-12
Neurocrine Biosciences USD 787.9M 7M 2025-12
Omeros USD -33.16M 18.52M 2024-06
Pacira USD 142.25M 11.34M 2025-12
Regeneron Pharmaceuticals USD 3.3B 67M 2025-12
Roche Holding CHF 22.09B 10.04B 2025-12
Sangamo BioSciences -2.39M 1.09M 2024-06
Surmodics USD 20.08M 31.62M 2025-06
Ultragenyx Pharmaceutical USD 178M 46.06M 2025-12
Veracyte USD 101.97M 10.69M 2025-12
Vertex Pharmaceuticals USD 2.72B 62.4M 2025-12